Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEMAMOOD: Semaglutide for Major Depressive Disorder and Overweight/Obesity
NCT07136714Phase 4Recruiting
- Sponsor
- Nordsjællands Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in major depressive disorder (MDD), sponsored by Nordsjællands Hospital. Started Sep 2025; status: recruiting.
02
Drugs
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07136714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07136714.